Introduction {#Sec1}
============

Amyloidosis is a rare disorder characterized by abnormal, misfolded proteins that accumulate in various organs, causing progressive organ damage \[[@CR1], [@CR2]\]. There are several types of systemic amyloidoses; light chain (AL) amyloidosis (Orpha number: ORPHA85443) represents the most common type \[[@CR3]\]. The estimated incidence of AL amyloidosis is 8--12 persons per million per year \[[@CR4]--[@CR6]\]. In addition, an estimated 10--15% of cases occur in association with multiple myeloma. Based on the incidence data, it is estimated that there are 30,000 to 45,000 patients living with AL amyloidosis in the United States and the European Union.

Clinical presentation of AL amyloidosis can vary widely and depends on the extent and number of organs affected. Initial symptoms at onset are often nonspecific (e.g., weight loss, fatigue). As the disease progresses, symptoms reflect the organs involved, most commonly the heart and the kidneys \[[@CR5]\]. The goal of treatment for patients with AL amyloidosis should be to preserve and improve organ function with a well-tolerated and effective disease-modifying therapy. Despite recent advances in AL amyloidosis diagnostic tools and treatment, the early mortality rate remains high; the 1-year mortality rate is approximately 30%. Unfortunately, by the time a diagnosis is made and treatment is initiated, the disease has often become advanced \[[@CR4], [@CR5]\].

In the absence of approved therapies for AL amyloidosis, physicians use off-label multiple myeloma therapies that target the abnormal plasma cells responsible for the production of the light chain precursor proteins without consideration for the underlying organ dysfunction in the patient \[[@CR5], [@CR7], [@CR8]\]. Thus, these treatments can be associated with significant adverse events, and patients often die before experiencing benefit from them \[[@CR5]\]. A substantial need remains for well-tolerated and effective therapies that specifically target the underlying cause of the disease: the misfolded light chain proteins.

Despite the significant effects of AL amyloidosis on patient quality of life, data describing them are lacking. Detailing the patient experience may identify ways to improve patient care and disease outcomes. The primary aim of this study was to gather data on the patient experience to elucidate the challenges in establishing a diagnosis of AL amyloidosis and to gain insight into barriers to accessing appropriate care.

Methods {#Sec2}
=======

Patients with amyloidosis, their family members, and their caregivers were invited to participate in an anonymous online survey through email and via the social media channels of the Amyloidosis Foundation ([www.amyloidosis.org](http://www.amyloidosis.org)), the foundation's Facebook page ([www.facebook.com/AmyloidosisFoundation](http://www.facebook.com/AmyloidosisFoundation)), and an amyloidosis awareness group on Facebook ([www.facebook.com/groups/amyloidosisawareness](http://www.facebook.com/groups/amyloidosisawareness)). The initial 16-question survey was developed by the authors and was available online to participants from January 29 to February 5, 2015. After the initial survey was completed, participants with AL amyloidosis who provided contact information were sent an eight-question follow-up survey by email.

The initial survey covered demographic information, type of amyloidosis, symptoms, organ involvement, diagnosis, amyloidosis education, and clinical trial awareness. It was expected that a high proportion of respondents to the initial survey would be patients with AL amyloidosis; therefore, the follow-up survey focused on AL amyloidosis and consisted of eight questions covering amyloidosis treatments, treatment tolerance, and quality of life before and after treatment.

Statistical Analysis {#Sec3}
--------------------

Data were evaluated using descriptive statistics (Microsoft Excel 2013, Redmond, Washington).

Compliance with Ethics Guidelines {#Sec500}
---------------------------------

This article does not contain information on any new studies in human or animal subjects performed by any of the authors. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964, as revised in 2013. Informed consent was obtained from all patients as a condition of their inclusion in the study.

Results {#Sec5}
=======

Participants {#Sec6}
------------

The initial survey was completed by 533 participants; 57.8% identified themselves as patients, 33.8% identified themselves as family members, and 8.3% identified themselves as caregivers taking the survey on behalf of patients (Table [1](#Tab1){ref-type="table"}). The follow-up survey was completed by 201 participants. Most respondents were female (62.2%) and were between 50 and 69 years of age (62.7%).Table 1Characteristics of survey respondentsRespondentsType of participant, *n* (%), *n* = 515 Patient298 (57.8) Family member174 (33.8) Caregiver43 (8.3)Sex, *n* (%), *n* = 519 Female323 (62.2) Male196 (37.8)Age group, *n* (%), *n* = 524 25--34 years23 (4.4) 35--44 years59 (11.3) 45--54 years96 (18.3) 55--64 years190 (36.3) 65--74 years120 (22.9) 75 years or older36 (6.9)Median age at diagnosis, years (range)57 (20--83)Type of amyloidosis, *n* (%), *n* = 484 AL amyloidosis347 (71.7) AA amyloidosis23 (4.8) Hereditary transthyretin-related amyloidosis35 (7.2) Hereditary non--transthyretin-related amyloidosis6 (1.2) Other25 (5.2) Unknown48 (9.9)Organ involvement, *n* (%), *n* = 469 Heart172 (36.7) Kidneys132 (28.1) Liver15 (3.2) Gastrointestinal tract27 (5.8) Nervous system26 (5.5) Multiple97 (20.7)Please note that not all participants responded to all questions. 533 participants completed the survey, but the numbers in the table indicate those who answered each particular survey question*AA* inflammatory, *AL* light chain

Diagnosis of Amyloidosis {#Sec7}
------------------------

Median age at diagnosis was 57 years (range 20--83 years). AL amyloidosis, reported by 71.7% of respondents (Table [1](#Tab1){ref-type="table"}), was the most common diagnosis. The other types of amyloidosis were AA amyloidosis (4.8%), hereditary transthyretin-related amyloidosis (7.2%), hereditary non--transthyretin-related amyloidosis (1.2%), other (5.2%), and unknown (9.9%).

Most respondents (63.0%) reported that they received a diagnosis of amyloidosis within 1 year of initial symptoms, whereas 37.1% of respondents reported that diagnosis was delayed for ≥1 year (Table [2](#Tab2){ref-type="table"}). A substantial proportion of respondents (31.8%) reported visiting ≥5 different physicians before receiving the diagnosis of amyloidosis, and only 7.6% received the diagnosis after visiting one physician (Table [2](#Tab2){ref-type="table"}). The first doctor seen was usually a primary care physician (64.9%). Respondents were then often referred for a second visit to a cardiologist (24.5%), hematologist/oncologist (16.5%), nephrologist (18.1%), or gastroenterologist (14.6%) (Fig. [1](#Fig1){ref-type="fig"}). Cardiologists, hematologists/oncologists, and nephrologists had the most opportunities to diagnose amyloidosis for respondents referred to their specialties. Respondents also visited other specialists, including internists, neurologists, hepatologists, ophthalmologists, and dermatologists.Table 2Establishment of amyloidosis diagnosisRespondentsTime from initial symptoms to diagnosis of amyloidosis, *n* (%), *n* = 459 \<6 months171 (37.3) 6--12 months118 (25.7) 12--18 months44 (9.6) 18--24 months34 (7.4) 2--3 years44 (9.6) \>3 years48 (10.5)Different physicians visited before establishment of a diagnosis, *n* (%), *n* = 459 135 (7.6) 2108 (23.5) 393 (20.3) 477 (16.8) ≥5146 (31.8)Specialty of diagnosing physician, *n* (%), *n* = 402 Hematologist/oncologist137 (34.1) Nephrologist91 (22.6) Cardiologist75 (18.7) Gastroenterologist32 (8.0) Neurologist19 (4.7) Primary care physician16 (4.0) Other^a^32 (8.0)^a^Includes internists, hepatologists, ophthalmologists, and dermatologistsFig. 1Types of physicians visited before diagnosis of amyloidosis

Respondents saw cardiologists more frequently than hematologists/oncologists and nephrologists, though cardiologists did not typically diagnose the condition. Respondents usually received the correct diagnosis from a hematologist/oncologist (34.1%). Nephrologists and cardiologists provided the correct diagnosis for 22.6% and 18.7% of respondents, respectively (Table [2](#Tab2){ref-type="table"}).

Sixty-three percent of respondents had been evaluated at an amyloidosis center (452 total responses), although only 43.7% received treatment at an amyloidosis center (444 total responses).

Amyloidosis Symptoms and Organ Involvement {#Sec8}
------------------------------------------

The most common initial symptoms were fatigue, shortness of breath, weakness, neuropathy, and swelling of the legs and/or tongue. Most respondents reported the heart (36.7%) or the kidneys (28.1%) as the major organ affected, with involvement of the gastrointestinal tract (5.8%), nervous system (5.5%) or liver (3.2%) reported less frequently (Table [1](#Tab1){ref-type="table"}). Multiple organ involvement was reported by 20.7% of respondents.

AL Amyloidosis Diagnosis and Treatment {#Sec9}
--------------------------------------

Among the participants with AL amyloidosis who completed the follow-up survey, 39.2% reported low quality of life before diagnosis, 31.2% reported average quality of life, and 29.7% reported great quality of life (199 total responses). When asked how the diagnosis of amyloidosis made the patient feel, 63.0% reported feeling frightened, 31.0% depressed, 30.5% numb, 28.5% powerless, 25.5% hopeless, 18.5% relieved, and 18.0% angry (200 total responses).

For patients with AL amyloidosis who responded to the follow-up survey, treatment consisted of chemotherapy in 63.1% of respondents, stem cell transplantation in 38.9%, and solid organ transplantation in 7.6%. When asked how well treatment was tolerated, 54.1% reported that it was somewhat or very difficult, 20.4% reported neither easy nor difficult, and 25.4% reported somewhat easy (181 total responses). However, patients receiving stem cell transplantation found treatment to be much less tolerable than patients receiving other types of treatment (Table [3](#Tab3){ref-type="table"}). Quality of life in patients receiving any of these treatments was greatly improved with treatment for 28.8% of respondents, somewhat improved for 39.1%, and not improved at all for 32.1% (184 total responses). In particular, patients receiving stem cell transplantation rated their quality of life as having improved more substantially than patients receiving other treatments (Table [3](#Tab3){ref-type="table"}).Table 3Tolerability and quality of life associated with stem cell transplantation compared with other treatmentsStem cell transplantation (*n* = 77)Other treatments (*n* = 124)Tolerability, *n* (%)*n* = 75*n* = 105 Very difficult20 (26.7)13 (12.4) Somewhat difficult28 (37.3)37 (35.2) Neither easy nor difficult14 (18.7)22 (21.0) Somewhat easy13 (17.3)33 (31.4)Quality of life, *n* (%)*n* = 76*n* = 108 Greatly improved28 (36.8)25 (23.1) Somewhat improved26 (34.2)46 (42.6) No improvement22 (28.9)37 (34.3)

Amyloidosis Education {#Sec10}
---------------------

Of the 427 respondents who answered a question pertaining to information or educational material received at the time of diagnosis about their specific amyloidosis type, 39.3% received the center's own printed handouts, 34.4% received another organization's disease or treatment literature, 29.3% received information on support groups, 23.7% received clinical trial information, and 40.0% reported receiving no information or educational material.

Clinical Trial Awareness {#Sec11}
------------------------

In the initial survey, participants were asked to score their answers regarding clinical trial knowledge and access on a scale of 1 to 5, from "Not at all" (score 1) to "Absolutely" (score 5) (Fig. [2](#Fig2){ref-type="fig"}). A significant number of respondents felt uninformed about clinical trials; 71.6% indicated a score of ≤3 regarding how knowledgeable they were about clinical trials. Most respondents also felt that they did not have access to pertinent clinical trial information; 68.8% indicated a score of ≤3 regarding access to clinical trial information. Nevertheless, almost half (46.1%) said they believed that a clinical trial would enhance their medical care (score of ≥4), and 45.5% reported that they would absolutely consider enrolling in a clinical trial if they were well informed. Forty-six percent of respondents also reported that they did not know how to enroll in a clinical trial. In the follow-up survey, 19.5% of respondents reported that they had participated in a clinical trial (190 total responses).Fig. 2Clinical trial awareness and interest

Discussion {#Sec12}
==========

Despite the challenges facing health care professionals in diagnosing AL amyloidosis, the lack of available therapeutic options that are effective and well tolerated, and the subsequent impact on the patients involved, no published information describes the patient experience. This article represents the first such description of the patient journey and the challenges faced.

Establishing an early and accurate diagnosis of amyloidosis is a challenge for patients. These data demonstrate that most patients require multiple physician visits to different medical specialists, often spanning \>1 year. Consistent with the literature \[[@CR5], [@CR9], [@CR10]\], most respondents experience heart or kidney involvement.

Because of the high incidence of cardiac symptoms (including shortness of breath) associated with AL amyloidosis, primary care physicians often refer their patients to cardiologists. There is an opportunity and an urgent need for all physicians, particularly cardiologists, to diagnose amyloidosis earlier, before the disease progresses to more advanced stages. These data suggest that physicians in all medical specialties have difficulty in establishing a diagnosis of AL amyloidosis. Interestingly, although AL amyloidosis is typically considered to be a disease of the elderly (older than 60 years of age), the median age of respondents in our survey was 57 years, with 34.0% younger than 55 years of age and 15.6% younger than 45 years of age. Despite a selection bias inherent in a web-based survey that may skew to younger persons, younger patients are also probably significantly underdiagnosed.

Considering that 54% of respondents had difficulty in tolerating treatment and only 30% of respondents reported a definite improvement in quality of life, there is a need for therapies clearly associated with treatment benefit. On the other hand, benefits from therapy are more likely to occur in early stages of the disease, making early diagnosis essential for improving outcomes for patients with systemic amyloidosis \[[@CR11]\]. Efforts to increase physician awareness of the signs and symptoms and the appropriate evaluation of AL amyloidosis have the potential to improve patient outcomes.

Survey responses indicate that patient awareness of clinical trials and patient education about the disease can be considerably improved, especially because respondents indicated a high willingness to participate in clinical trials. Patient care can be enhanced through education and information to help patients feel empowered and knowledgeable about their diagnosis and treatment plan and through increased access to support groups and relevant clinical trials.

We acknowledge the limitations in controlling the quality of information gathered through a web-based questionnaire. Of note, there is a selection bias inherent to a web-based survey that includes a younger audience of patients and/or younger persons involved in their care. However, we show that this younger population, which likely represents the most knowledgeable segment of patients and which has the best access to Internet resources, is not very well informed. Additionally, there may be a bias with respect to sex given that several studies have shown that men have a higher incidence of most forms of amyloidosis, whereas our respondents were primarily women (62%). Web-based surveys also do not control for the quality of care patients are receiving; as such, it is not known whether the respondents represent patients with better or worse (or equivalent) care than the average amyloidosis patient. Nevertheless, this patient-centered initiative provides important insights into the AL amyloidosis patient experience from the time of diagnosis through treatment of the disease.

Conclusions {#Sec13}
===========

This study highlights the value of and the need for data on patient experience and quality of life that can be reported in future studies as part of patient-centered initiatives. Data from this study and other studies can help to identify areas in which diagnosis is delayed or missed and can illustrate the need for early, accurate diagnosis of amyloidosis to help improve disease management and survival outcomes.
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